ISU Abxis Co., Ltd. (KOSDAQ:086890)

Market Cap	229.40B
Revenue (ttm)	66.39B
Net Income (ttm)	28.14B
Shares Out	39.69M
EPS (ttm)	636.99
PE Ratio	9.07
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	105,517
Average Volume	413,498
Open	5,780.00
Previous Close	5,800.00
Day's Range	5,700.00 - 5,840.00
52-Week Range	4,240.00 - 6,350.00
Beta	0.44
RSI	51.08
Earnings Date	Aug 8, 2025

About ISU Abxis

ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; Clotinab, an abciximab that is used as an adjunct to percutaneous coronary inte...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2001
• Employees: 178
• Stock Exchange: KOSDAQ
• Ticker Symbol: 086890

Financial Performance

In 2024, ISU Abxis's revenue was 60.26 billion, an increase of 10.96% compared to the previous year's 54.31 billion. Earnings were 14.72 billion, an increase of 307.63%.